Trevena (NASDAQ:TRVN) Stock Crosses Below 200 Day Moving Average of $0.56

Trevena, Inc. (NASDAQ:TRVN)’s stock price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.56 and traded as low as $0.40. Trevena shares last traded at $0.44, with a volume of 112,979 shares trading hands.

Analyst Ratings Changes

TRVN has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of Trevena in a research note on Tuesday, April 2nd. StockNews.com initiated coverage on shares of Trevena in a research report on Wednesday. They issued a “sell” rating on the stock.

Trevena Trading Up 5.5 %

The company has a current ratio of 4.66, a quick ratio of 4.66 and a debt-to-equity ratio of 8.35. The firm has a market cap of $8.06 million, a PE ratio of -0.14 and a beta of 1.11. The firm has a fifty day simple moving average of $0.46 and a two-hundred day simple moving average of $0.56.

Trevena (NASDAQ:TRVN) last released its quarterly earnings results on Monday, April 1st. The biopharmaceutical company reported ($1.06) earnings per share for the quarter. The company had revenue of ($0.08) million for the quarter, compared to analyst estimates of $0.09 million. Equities analysts forecast that Trevena, Inc. will post -1.28 EPS for the current year.

Hedge Funds Weigh In On Trevena

A hedge fund recently bought a new stake in Trevena stock. Jump Financial LLC bought a new position in Trevena, Inc. (NASDAQ:TRVN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 44,396 shares of the biopharmaceutical company’s stock, valued at approximately $27,000. Jump Financial LLC owned approximately 0.32% of Trevena as of its most recent filing with the SEC. Hedge funds and other institutional investors own 13.56% of the company’s stock.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.